Table 3. Regimens Used in First Relapse
| Eligibility (mo) | Regimen | Patient Number | Comparator | Comments on Outcome (mo) |
| Most Commonly Used | ||||
| Platinum sensitive (>6) | Cisplatin or carboplatin + paclitaxel | 802 | Single or nontaxane + platinums | PFS 11 vs. 9; OS 24 vs. 19 [5] |
| Platinum sensitive (>6) | Carboplatin + gemcitabine | 356 | Carboplatin | PFS 8.6 vs. 5.8; OS 18 vs. 17 [6] |
| Platinum sensitive (> 6) | Carboplatin + pegylated liposomal doxorubicin | 976 | Carboplatin + paclitaxel | PFS 11.3 vs 9.4; OS not reported [7] |
| Other Regimens | ||||
| Platinum sensitive (>6) | Carboplatin + epirubicin | 190 | Carboplatin | Powered for response differences; OS 17 vs. 15 [5] |
| Platinum sensitive (≥12) | Cisplatin + doxorubicin + cyclophosphamide | 97 | Paclitaxel | PFS 15.7 vs. 9; OS 34.7 vs. 25.8 [6] |
| Platinum sensitive + resistant | PLD + trabectedina | 672 | PLD | PFS 7.3 vs. 5.8; OS 20.5 vs. 19.4b |
| OS = overall survival; PFS = progression-free survival; PLD = pegylated liposomal doxorubicin. | ||||
| aTrabectedin has been approved for use in treating recurrent ovarian cancer in Europe and Canada. | ||||
| bOS data were not mature at the time the manuscript was published.[4] |
References
- Monk BJ, Herzog TJ, Kaye SB, et al.: Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol 28 (19): 3107-14, 2010. [PUBMED Abstract]
- Bolis G, Scarfone G, Giardina G, et al.: Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer. Gynecol Oncol 81 (1): 3-9, 2001. [PUBMED Abstract]
- Cantù MG, Buda A, Parma G, et al.: Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol 20 (5): 1232-7, 2002. [PUBMED Abstract]
- Pfisterer J, Plante M, Vergote I, et al.: Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24 (29): 4699-707, 2006. [PUBMED Abstract]
